Which drug works by blocking the NPC1L1 transporter in the intestine?
Choose an answer, then check it.
Clinical Pharmacology · Lipid and Blood Disorder Medications
Other Lipid-Lowering Medications
On this page 6 sections
In 30 seconds
Statins are first-line for lowering LDL, but many patients need more help or cannot tolerate them, and that is where this drug family fits. Ezetimibe blocks intestinal cholesterol absorption and is the usual first add-on to a statin. PCSK9 inhibitors and inclisiran are injectables reserved for high residual risk. Fibrates, niacin, and omega-3s mainly target triglycerides, while bile acid sequestrants and bempedoic acid fill narrower niche roles.
The college version
The organizing idea across this family is matching the agent to the specific lipid abnormality left over after maximally tolerated statin therapy, or used when statins cannot be tolerated at all.
Ezetimibe
Ezetimibe inhibits the NPC1L1 transporter on intestinal enterocytes, the protein responsible for absorbing dietary and biliary cholesterol from the gut. Less cholesterol delivered to the liver prompts the liver to upregulate LDL receptors, pulling more LDL from the blood. Because its mechanism differs entirely from a statin's, its effect is additive, making it the typical first add-on when a statin alone falls short. Its side-effect profile is mild, with little muscle or liver toxicity.
PCSK9 Inhibitors and Inclisiran
Alirocumab and evolocumab are injectable monoclonal antibodies that block PCSK9, a liver protein that normally marks LDL receptors for degradation. Neutralizing PCSK9 lets the liver keep more receptors on its surface, clearing LDL far more effectively than oral therapy. These are reserved for familial hypercholesterolemia or established cardiovascular disease with LDL still above goal. Inclisiran targets the same pathway differently: it is a small interfering RNA that silences the liver's production of PCSK9 messenger RNA. Because its effect persists as the drug is slowly processed, inclisiran needs only infrequent dosing, an adherence advantage over the antibodies.
Bempedoic Acid
Bempedoic acid inhibits ATP-citrate lyase, an enzyme upstream of HMG-CoA reductase in the same synthesis pathway statins target. It requires activation by an enzyme found mainly in the liver, not skeletal muscle, so it largely spares muscle tissue, making it useful for statin-intolerant patients. Concerns include elevated uric acid, which can precipitate gout, and increased tendon rupture risk.
Bile Acid Sequestrants
Cholestyramine, colesevelam, and colestipol bind intestinal bile acids, blocking their reabsorption and forcing the liver to divert cholesterol into making new bile acids, lowering LDL. Not systemically absorbed, they are considered safe in pregnancy, but cause GI bulk, bloating, and constipation, can raise triglycerides, and bind other oral drugs and fat-soluble vitamins in the gut, requiring spaced dosing.
Fibrates
Fenofibrate and gemfibrozil are PPAR-alpha agonists that lower triglycerides by boosting lipoprotein lipase activity, making them first choice when severe hypertriglyceridemia raises pancreatitis risk rather than LDL. Combining gemfibrozil with a statin significantly raises myopathy and rhabdomyolysis risk through a pharmacokinetic interaction, so fenofibrate is generally preferred when a fibrate-statin combination is unavoidable.
Niacin
Niacin raises HDL and lowers triglycerides and LDL, but outcome trials failed to show added cardiovascular benefit on top of statin therapy, and it causes uncomfortable prostaglandin-mediated flushing, which aspirin pretreatment can blunt. This poor risk-benefit tradeoff has pushed niacin out of routine use.
Omega-3 Fatty Acids
Fish oil-derived omega-3s lower triglycerides. Icosapent ethyl, a purified formulation, has shown cardiovascular benefit in select high-risk patients with elevated triglycerides, distinguishing it from generic over-the-counter fish oil.
Lomitapide and Evinacumab
These niche agents treat homozygous familial hypercholesterolemia. Lomitapide blocks lipoprotein assembly in the liver and intestine; evinacumab inhibits ANGPTL3, lowering LDL independent of the LDL receptor pathway, valuable when receptor function itself is severely impaired.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of cholesterol as too many toy cars filling a room, with different tools cleaning up in different ways. Ezetimibe is a guard at the door stopping new toy cars from coming in. PCSK9 inhibitors and inclisiran protect the cleanup crew (the liver's receptors) from getting fired, so they keep grabbing cars off the floor. Bempedoic acid works back in the toy factory, but only the liver's factory, so muscles are never bothered. Bile acid sequestrants act like a sponge soaking up bile, forcing the body to make new bile from cholesterol. Fibrates, niacin, and fish oil mostly handle a different mess, greasy triglycerides, not the toy cars themselves. Each tool gets picked based on which mess is still on the floor after the main cleanup crew, the statin, has already done its work.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with familial hypercholesterolemia remains well above LDL goal despite maximally tolerated statin and ezetimibe therapy. What class of injectable therapy might be added next, and how does it lower LDL?
Show answer
A PCSK9 inhibitor (or inclisiran)
Since this patient is already maxed out on statin plus ezetimibe and still has high LDL from familial hypercholesterolemia, an injectable PCSK9 inhibitor like alirocumab or evolocumab, or the siRNA agent inclisiran, is a reasonable next step because it protects the liver's LDL receptors from being broken down, pulling more LDL out of the blood.
A patient taking colestipol reports new bloating and constipation, and the prescriber notices the patient's other oral medications seem less effective lately. Explain why both problems are occurring.
Show answer
Bile acid sequestrant side effects and drug interactions
Colestipol is a resin that sits in the gut and adds bulk, causing the bloating and constipation, and because it isn't selective, it also binds nearby oral medications, preventing them from being absorbed properly, which explains why the patient's other drugs seem less effective.
Quick check
3 questions here. Answers stay hidden until you check.
Combining gemfibrozil with a statin is especially risky because it raises the risk of which adverse effect?
Choose an answer, then check it.
What distinguishes bempedoic acid's site of activation from that of a statin?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.